|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Vasohibin-2-overexpressing HepG2-VASH2 (355 amino acid residues) and HepG2-VASH2-V5 (311 amino acid residues fused with V5 tag at the c-terminus) human liver cancer cell lines were established.
|
23615928 |
2013 |
|
Adult Solid Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Vasohibin-2 was recently identified as an important pro-angiogenesis factor in solid tumor and intracellular localization of its variants is important for elucidating the downstream mechanism(s) of its effects.
|
23615928 |
2013 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
VASH2 knockdown decreased, whereas VASH2 overexpression increased tubulin detyrosination of PDAC cells, and tubulin carboxypeptidase (TCP) inhibitor parthenolide inhibited VASH2-induced cell migration.
|
31074083 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Overall, VASH2 may promote drug resistance of breast cancer cells through regulating ABCG2 via the AKT signaling pathway.
|
29039601 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings suggest that VASH2 drives breast cancer cells to undergo EMT by activation of the TGFβ1 pathway and hypoxia dependent repression GATA3-ESR1 pathway, leading to cancer metastasis.
|
27867016 |
2017 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, VASH2 expression is positively correlated with FGF2 expression and promotes angiogenesis in human luminal breast cancer by transcriptional activation of fibroblast growth factor 2 through non-paracrine mechanisms.
|
27702660 |
2016 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
MCF‑7 and BT474 human breast cancer cells were transfected with lentiviral constructs to generate in vitro VASH2 overexpression and knockdown models.
|
24920244 |
2014 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Vasohibin 2 (VASH2) was previously identified as an angiogenic factor, but its role in TNBC tumorigenesis is unknown.
|
28670379 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Vasohibin 2 (VASH2) was previously identified as an angiogenic factor, but its role in tumorigenesis is unknown.
|
22614011 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
To further demonstrate the effectiveness of molecular targeting of VASH2 for anticancer treatment, we applied in vivo delivery of siRNA targeting VASH2 (siVASH2) using atelocollagen to a xenograft model of ovarian cancer.
|
24118388 |
2013 |
|
Childhood Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Vasohibin-2 was recently identified as an important pro-angiogenesis factor in solid tumor and intracellular localization of its variants is important for elucidating the downstream mechanism(s) of its effects.
|
23615928 |
2013 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
Microinjection of miR-181a-5p mimics and inhibitors led to abnormal expressions (20-50%) of two key target genes (pax2a and vash2) by WISH, and increased malformation percentages (18-45%) by IOD analysis.
|
30784759 |
2019 |
|
Deformity
|
0.010 |
Biomarker
|
group |
BEFREE |
Microinjection of miR-181a-5p mimics and inhibitors led to abnormal expressions (20-50%) of two key target genes (pax2a and vash2) by WISH, and increased malformation percentages (18-45%) by IOD analysis.
|
30784759 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, diabetes-induced increase in glomerular volume and reduction in glomerular slit-diaphragm density were significantly improved in VASH2 knockout mice.
|
29641565 |
2018 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
Accordingly, diabetes-induced increase in glomerular volume and reduction in glomerular slit-diaphragm density were significantly improved in VASH2 knockout mice.
|
29641565 |
2018 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, we investigated the pathogenic roles of VASH2 in diabetic nephropathy using VAHS2-deficient mice.
|
29641565 |
2018 |
|
Eye Color
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans.
|
23548203 |
2013 |
|
Eye Color
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association studies identify several new loci associated with pigmentation traits and skin cancer risk in European Americans.
|
23548203 |
2013 |
|
Intestinal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Employing adenomatous polyposis coli gene mutant mice, we recently reported on the role of Vash2 in the spontaneous formation of intestinal tumors.
|
28960674 |
2017 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Vasohibin-2-overexpressing HepG2-VASH2 (355 amino acid residues) and HepG2-VASH2-V5 (311 amino acid residues fused with V5 tag at the c-terminus) human liver cancer cell lines were established.
|
23615928 |
2013 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of VASH2 via siRNA inhibited the proliferation of the hepatoma cell lines by delaying cell cycle progression and increasing apoptosis.
|
22614011 |
2013 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Knockdown of VASH2 via siRNA inhibited the proliferation of the hepatoma cell lines by delaying cell cycle progression and increasing apoptosis.
|
22614011 |
2013 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Overall, VASH2 may promote drug resistance of breast cancer cells through regulating ABCG2 via the AKT signaling pathway.
|
29039601 |
2017 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
These findings suggest that VASH2 drives breast cancer cells to undergo EMT by activation of the TGFβ1 pathway and hypoxia dependent repression GATA3-ESR1 pathway, leading to cancer metastasis.
|
27867016 |
2017 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, VASH2 expression is positively correlated with FGF2 expression and promotes angiogenesis in human luminal breast cancer by transcriptional activation of fibroblast growth factor 2 through non-paracrine mechanisms.
|
27702660 |
2016 |